New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025

Key Takeaways

• Lebrikizumab continues to show strong real-world outcomes for atopic dermatitis (AD).

• Interim data released by Almirall suggest tildrakizumab enhances psychological well-being in psoriasis patients.

New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.

The company, through two focused symposia at the conference, presented posters from the ADvocate 1 and 2 trials and the ADvantage study, showing lebrikizumab (alone and in combo with topical corticosteroids) improves skin symptoms and psychological well-being in moderate-to-severe AD patients through 52 weeks. 

“The real-life results are consistent with, or even surpass, those observed in registration studies,” said Dr. Silvia Ferrucci of IRCCS Ca' Granda Foundation, Milan, in a press release.

Almirall also published interim data from the POSITIVE study showing tildrakizumab improving key symptoms and psychological wellbeing in moderate-to-severe plaque psoriasis. It was the first study to use the WHO-5 Well-being Index as a primary endpoint.

The company also hosted the PsOlve Challenge finale, promoting holistic care strategies in psoriasis.

“Our participation in ICD reflects our ongoing commitment to patient-focused dermatologic innovation,” said Dr. Volker Koscielny, Almirall’s Chief Medical Officer, in the news release.

Source: Almirall news release. June 19, 2025.